Buy & Sell Vanguard S&P 500 Growth Index Fund ETF (VOOG) – Vanguard S&P 500 Growth Index Fund ETF Price Today
Key Stats
- -Market Cap
- Broad Market / FactorSector
- -9.45%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 99% Buy | 1% SellTrading Activity
- 13 daysTypical Hold Time
Over the past 52 weeks, Vanguard S&P 500 Growth Index Fund ETF has traded between a low of $62.22 and a high of $84.35, highlighting its annual price range. Over the past three months, Vanguard S&P 500 Growth Index Fund ETF has recorded a drawdown of -9.45%, reflecting recent price volatility. On average, investors hold Vanguard S&P 500 Growth Index Fund ETF for approximately 13 days, indicating typical investor behavior on the platform.
About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Most Recent News
ExxonMobil warns oil prices could spike to $160/barrel amid low inventories and geopolitical tensions.
ExxonMobil's Senior Vice President Neil Chapman warned that crude oil prices could surge to $150-$160 per barrel soon due to critically low inventory levels, despite recent price drops linked to U.S.-Iran peace talks. The company highlighted that str...

XRP shows signs of bottoming as smart money accumulates and ETFs hit best month of 2026.
XRP has shown signs of bottoming after a five-month consolidation, with smart money investors increasing accumulation. XRP ETFs recorded their best month in 2026, adding $131 million in inflows in May, contrasting with declines in Bitcoin and Ethereu...

Whitehawk reveals SEZ6 as a promising target for new cancer drug HWK-206, advancing to clinical trials in 2026.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
